medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-12-12-17medsovet-2557Research ArticleКАРДИОЛОГИЯCARDIOLOGYАктуальные вопросы применения бета-адреноблокаторов в различных клинических ситуацияхTopical issues of beta-blockers use in various clinical situationsНебиеридзеД. В.NebieridzeD. V.

д.м.н., профессор

ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России, МоскваРоссияNational Medical Research Center for Preventive Medicine, Federal Budgetary Healthcare Institution of the Ministry of Health of Russia, MoscowRussian Federation2018240720180121217Copyright © Небиеридзе Д.В., 20182018Небиеридзе Д.В.Nebieridze D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2557

В обзоре анализируются актуальные вопросы применения бета-блокаторов в клинической практике. Обращается внимание практических врачей на возможности применения тех или иных бета-блокаторов в различных клинических ситуациях. Некоторые бета-блокаторы, особенно неселективные, обладают отрицательными эффектами и не могут быть использованы в определенных клинических ситуациях (метаболический синдром, сахарный диабет 2-го типа). Современные суперселективные бета-блокаторы не обладают указанными отрицательными эффектами и могут широко применяться в клинической практике, в том числе при метаболическом синдроме и СД 2-го типа. В обзоре акцент сделан на метопролола тартрат, который имеет наиболее широкую доказательную базу эффективности при различных ССЗ. Еще одной проблемой, относящейся к бета-блокаторам, является нечастое их назначение или использование в недостаточных дозах. В связи с  этим практическому врачу необходимо смелее назначать их в рекомендованных терапевтических дозах, согласно инструкции по медицинскому применению лекарственного препарата, в различных клинических ситуациях.

 

The article provides a review of the topical issues of beta-blockers use in the clinical practice. Attention of practitioners is drawn to the possibility of using these or other beta-blockers in various clinical situations. Some beta-blockers, especially non-selective ones, have negative effects and cannot be used in certain clinical situations (metabolic syndrome, type 2 diabetes mellitus). Modern super-selective beta-blockers do not have these negative effects and can be widely used in clinical practice, including metabolic syndrome and type 2 diabetes. The review focuses on metoprolol tartrate, which has the most extensive evidence base for efficient treatment of various cardiovascular diseases. Another problem related to beta-blockers is their infrequent use or use at inadequate doses. In this connection, a practitioner should prescribe them at the recommended therapeutic doses in various clinical situations, according to the instructions for use of the drug.

 

бета-блокаторыметаболические эффектычастота сердечных сокращенийметопролола тартратbeta-blockersmetabolic effectsheart ratemetoprolol tartrateReferencesДиагностика и лечение артериальной гипертензии. Российские рекомендации V пересмотр. Кардиологический вестник, 2015, 1(10): 3-30.Diagnosis and treatment of arterial hypertension. Russian guidelines, V revision. Kardiologicheskiy Vestnik, 2015, 1 (10): 3-30.Диагностика и лечение хронической ишемической болезни сердца: Клинические рекомендации МЗ РФ, 2013 г. РКНПК [Электронный ресурс], 10.12.2014. URL: http://www.cardioweb.ru/klinicheskierekomendatsii.Diagnosis and treatment of chronic ischemic heart disease: Clinical recommendations of the Ministry of Health of the Russian Federation, 2013 RKNPK [Electronic resource], 10.12.2014. URL: http://www.cardioweb.ru/klinicheskierekomendatsii.Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН. Сердечная недостаточность, 2013, 14, 7(81): 379-472.National guidelines for the diagnosis and treatment of CHF of the Heart Failure Association, the Russian Society of Cardiology and the Russian Scientific Medical Society of Physicians. Serdechnaya Nedostatochnost, 2013, 14, 7 (81): 379-472.Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke and coronary heart disease. Part II: Effects of short term-reductions of blood pressure – an overview of the unconfined randomized drug trials in an epidemiological context. Lancet, 1990, 335: 827-838.Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke and coronary heart disease. Part II: Effects of short term-reductions of blood pressure – an overview of the unconfined randomized drug trials in an epidemiological context. Lancet, 1990, 335: 827-838.Kaplan M. Metabolic Aspects of Hypertension. Science press 1994, London.Kaplan M. Metabolic Aspects of Hypertension. Science press 1994, London.Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. JACC, 1995, 25: 1327-32.Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. JACC, 1995, 25: 1327-32.Berne C, Pollare T, Lithell H: Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care, 1991, 14(suppl 4): 39-47.Berne C, Pollare T, Lithell H: Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care, 1991, 14(suppl 4): 39-47.Lithell H: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care, 1991, 14: 203-209.Lithell H: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care, 1991, 14: 203-209.Reneland R, Alvares E, Andersson PL, et al. Induction of insulin resistance by beta-block-ade but not by ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens, 2000, 14: 175-180.Reneland R, Alvares E, Andersson PL, et al. Induction of insulin resistance by beta-block-ade but not by ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens, 2000, 14: 175-180.Veterans Administration Cooperative Study Group on Antihypertensive Agents: Propranolol or HCTZ alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Hypertension, 1985, 7: 1008-1016.Veterans Administration Cooperative Study Group on Antihypertensive Agents: Propranolol or HCTZ alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Hypertension, 1985, 7: 1008-1016.The Working Group on Hypertension in diabetes: Statement on hypertension in diabetes mellitus. Final report. Arch Int Med, 1987, 147: 830-842.The Working Group on Hypertension in diabetes: Statement on hypertension in diabetes mellitus. Final report. Arch Int Med, 1987, 147: 830-842.Pool PE, Seagren SC, Salel AF. Metabolic consequences of treating hypertension. Am J Hypertens, 1991, 4: 494-502.Pool PE, Seagren SC, Salel AF. Metabolic consequences of treating hypertension. Am J Hypertens, 1991, 4: 494-502.Weidmann P, Feffier C, Saxenhofer H, et al: Serum lipoproteins during treatment with antihypertensive drugs. Drugs, 1988, 35(suppl 6): 118-134.Weidmann P, Feffier C, Saxenhofer H, et al: Serum lipoproteins during treatment with antihypertensive drugs. Drugs, 1988, 35(suppl 6): 118-134.Pepine CJ, Handberg EM, Cooper-DeHoff RM, еt al. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Tretment Strategy for Patients With Coronary Artery Disease The International Verapamil SR/Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA, 2003 December 3, 21(290): 2805-16.Pepine CJ, Handberg EM, Cooper-DeHoff RM, еt al. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Tretment Strategy for Patients With Coronary Artery Disease The International Verapamil SR/Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA, 2003 December 3, 21(290): 2805-16.The ALLHAT Officers and Coordinators Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA, 2002, 288: 2981-97.The ALLHAT Officers and Coordinators Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA, 2002, 288: 2981-97.Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet, 2002, 359: 995-1003.Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet, 2002, 359: 995-1003.Beevers DG. The end of beta-bockers for uncomplicated hypertension? Lancet, 2005, 366: 1510-1512.Beevers DG. The end of beta-bockers for uncomplicated hypertension? Lancet, 2005, 366: 1510-1512.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults / P.K.Whelton (chair) Hypertension. November, 13, 2017. 481 p.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults / P.K.Whelton (chair) Hypertension. November, 13, 2017. 481 p.Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension: morbidity results from the MAPHY Study. Hypertension, 1991, 17: 579-88.Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension: morbidity results from the MAPHY Study. Hypertension, 1991, 17: 579-88.Линчак Р.М., Шумилова К.М., Мартынюк А.Д., Гусаим Т.А., Семенова Е.В., Жирова Л.Г., Бойцов С.А. Применение комбинированного препарата лозартана и гидрохлортиазида в антигипертензивной терапии. Рациональная фармакотерапия в кардиологии, 2006, 2(1): 18-26.Lynchak RM, Shumilova KM, Martynyuk AD, Gusaim TA, Semenova EV, Zhirova LG, Boytsov SA The use of a combined drug losar-tan and hydrochlorothiazide in antihypertensive therapy. Rational pharmacotherapy in cardiology, 2006, 2 (1): 18-26.Линчак Р.М. Сравнительная эффективность фиксированной комбинации периндоприл/ индапамид у больных артериальной гипертензией различного пола и возраста. Кардиология, 2010, 50(6): 35-40.Linchak RM. Comparative efficacy of a fixed combination of perindopril/indapamide in patients with arterial hypertension of different sex and age. Kardiologiya, 2010, 50 (6): 35-40.Небиеридзе Д.В., Сафарян А.С., Выгодин В.А., Драпкина О.М., Бойцов С.А. Современные возможности достижения целевого артериального давления у пациентов с артериальной гипертонией в условиях амбулаторной практики: результаты исследования ЛИДЕР. Рациональная фармакотерапия в кардиологии, 2018, 14(1): 12-20.Nebieridze DV, Safaryan AS, Vygodin VA, Drapkina OM, Boytsov SA. The modern possibilities for achieving target blood pressure in patients with arterial hypertension in ambulatory practice: the results of LEADER study. Ratsionalnaya Farmakoterapiya V Kardiologii, 2018, 14 (1): 12-20.Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/ trandolapril STudy (INVEST). Eur Heart J, 2008, 29: 1327-1334.Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/ trandolapril STudy (INVEST). Eur Heart J, 2008, 29: 1327-1334.Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J, 1985, 6(3): 199-226.Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J, 1985, 6(3): 199-226.Herlitz J1, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). Am J Cardiol, 1997, 13, 80(9B): 40J-44J.Herlitz J1, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). Am J Cardiol, 1997, 13, 80(9B): 40J-44J.Roberts R1, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, Willerson JT, Knatterud GL, Forman S, Passamani E, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation, 1991, 83(2): 422-37.Roberts R1, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, Willerson JT, Knatterud GL, Forman S, Passamani E, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation, 1991, 83(2): 422-37.Coletta C, Ricci R, Ceci V, Seccareccia F, Rulli F, Mazzuca V, Putini RL, Salustri A, Bottero G, Pasquale M. Effects of early treatment with captopril and metoprolol singly or together on six-month mortality and morbidity after acute myocardial infarction. Results of the RIMA (Rimodellamento Infarto Miocardico Acuto) study. The RIMA researchers. G Ital Cardiol, 1999, 29(2): 115-24.Coletta C, Ricci R, Ceci V, Seccareccia F, Rulli F, Mazzuca V, Putini RL, Salustri A, Bottero G, Pasquale M. Effects of early treatment with captopril and metoprolol singly or together on six-month mortality and morbidity after acute myocardial infarction. Results of the RIMA (Rimodellamento Infarto Miocardico Acuto) study. The RIMA researchers. G Ital Cardiol, 1999, 29(2): 115-24.Olsson G, Rehnqvist N, Sjogren A, Erhardt L, Lundman T. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol, 1985, 5(6): 1428-37.Olsson G, Rehnqvist N, Sjogren A, Erhardt L, Lundman T. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol, 1985, 5(6): 1428-37.Ibanez B1, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A, Fernandez-Ortiz A, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation, 2013, 1, 128(14): 1495-503.Ibanez B1, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A, Fernandez-Ortiz A, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation, 2013, 1, 128(14): 1495-503.Яковлев В.Т. Опыт применения кардиоселективного р-адреноблокатора Эгилока (метопролола) для лечения нарушений сердечного ритма. Консилиум, 2001, 1(19): 22-24.Yakovlev VT. Experience in using cardioselective p-adrenergic blocker Egiloc (metoprolol) in treatment of cardiac arrhythmias. Consilium, 2001, 1 (19): 22-24.Подзолков В.И., Исайкина О.Ю., Самойленко В.В., Маколкин В.И. Клиническая эффективность s-адреноблокатора метопролола у больных гипертонической болезнью. Росс. кардиол. Журнал, 2000, 4: 41-44.Podzolkov VI, Isaykina OYu, Samoylenko VV, Makolkin VI. Clinical efficacy of s-adrenoblocker metoprolol in hypertensive patients. Ross. Kardiol. Zhurnal, 2000,Кулешова Э.В., Лоховицина Н.Л., Цай Н.В. Антиангинальная и антиишемическая активность ЭгилокаR у больных стенокардией напряжения. Клин. фармакол. терапия, 2001, 1: 85-87.4: 41-44.Gibbons RJ, Chatterjee K, Daley J et al. ACC/ AHA/ACP-ASIM guidelines for themanagement of patientswith chronic stable angina: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol, 1999, 33(7): 2092-197.Kuleshova EV, Lokhovitsina NL, Tsai NV. Antianginal and antiischemic activity of Egilok R in patients with angina pectoris. Klin. Farmakol. Terapiya, 2001, 1: 85-87.Кобалава Ж.Д., Киякбаев Г.К., Хомицкая Ю.В., Шаваров А.А. Достижение целевого уровня частоты сердечных сокращений покоя у пациентов со стабильной стенокардией и артериальной гипертонией на фоне терапии β-адреноблокаторами в реальной клинической практике. Кардиология, 2013, 7: 1-11Gibbons RJ, Chatterjee K, Daley J et al. ACC/ AHA/ACP-ASIM guidelines for themanagement of patientswith chronic stable angina: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol, 1999, 33(7): 2092-197.The MERIT-HF investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Interven tion Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353: 2001-2007.Kobalava ZhD, Kiyakbaev GK, Khomitskaya YuV, Shavarov AA. Achieving the target level of resting heart rate in patients with stable angina and arterial hypertension on the top of therapy with β-adrenoblockers in real clinical practice. Kardiologiya, 2013, 7: 1-11.The MERIT-HF investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Interven tion Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353: 2001-2007.The MERIT-HF investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Interven tion Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353: 2001-2007.

The authors declare that there are no conflicts of interest present.